Alena A Katok
Biographic Data
| ID | 7956927 |
|---|---|
| NAME | Alena A Katok |
| GIVEN NAMES | Alena A |
| FAMILY NAME | Katok |
| SIGNATURE | KATOK A A |
| AFFILIATIONS | Kazan State Medical University |
| ORCID | 0000-0001-9046-3532 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)
The results of this study suggest early effect of cariprazine on negative symptoms at least in some schizophrenia patients with predominantly negative symptoms starting from 1 to 2 weeks of treatment and could be useful for determination of early clinical predictors for efficacy. Considering limitations of open-label design with no control groups these data need to be confirmed
No prominent works on this page.
Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)
The results of this study suggest early effect of cariprazine on negative symptoms at least in some schizophrenia patients with predominantly negative symptoms starting from 1 to 2 weeks of treatment and could be useful for determination of early clinical predictors for efficacy. Considering limitations of open-label design with no control groups these data need to be confirmed
Adverse effect (1 work) · Agonist (1 work) · Akathisia (1 work) · Antipsychotic (1 work) · Dopamine (1 work) · Dopamine receptor D2 (1 work) · Dopamine receptor D3 (1 work) · Extrapyramidal symptoms (1 work) · Internal Medicine (1 work) · Lurasidone (1 work)